SANGAMO THERAPEUTICS INC (SGMO) 3.65 +0.09 (+2.53%)
3.65 +0.09 (+2.53%)
US8006771062 - Common Stock - After market: 3.74 +0.09 (+2.47%)
Fundamental Rating
Taking everything into account, SGMO scores 3 out of 10 in our fundamental rating. SGMO was compared to 634 industry peers in the Biotechnology industry. SGMO has a bad profitability rating. Also its financial health evaluation is rather negative. SGMO has a expensive valuation and it also scores bad on growth
Profitability
Profitability Rating
SGMO's Return On Assets of -29.94% is amongst the best of the industry. SGMO does better than the industry average Return On Assets of -44.83%.
SGMO has a Profit Margin of -158.67%. This is better than the industry average of -464.10%.
SGMO has negative profitability rations, so we won't be analyzing them here.
SGMO has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for SGMO.
VS Industry
ROA (-29.94%) VS Industry: 73% outperformed.
-3,944.82
115.38
Profit Margin (-158.67%) VS Industry: 67% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
When comparing the current price to the book value of SGMO, we can conclude it is valued correctly. It is trading at 1.93 times its book value.
When comparing the price book ratio of SGMO to the average industry price book ratio of 1.73, SGMO is valued in line with its industry peers.
SGMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMO. No positive earnings are expected for the next year.
VS Industry
Price/Book (1.93) VS Industry: 45% outperformed.
134.78
0.10
Growth
Growth Rating
Measured over the past 5 years, SGMO shows a very strong growth in Revenue. The Revenue has been growing by 41.67% on average per year.
The Earnings Per Share has been growing slightly by 6.30% over the past year.
The Earnings Per Share is expected to decrease by -1.23% on average over the next 5 years.
Looking at the last year, SGMO shows a small growth in Revenue. The Revenue has grown by 3.26% in the last year.
SGMO is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 7.16% yearly.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 6.3% | -8.58% | -4.63% | -1.58% | -1.23% |
| Revenue | 41.67% | 9.42% | 3.26% | 1.08% | 6.28% | 9.18% | 7.16% |
Health
Health Rating
A Current Ratio of 2.75 indicates that SGMO has no problem at all paying its short term obligations.
SGMO has a Quick Ratio of 2.75. This indicates that SGMO is financially healthy and has no problem in meeting its short term obligations.
The Debt to Equity ratio of SGMO is in line with the industry averages.
The Altman-Z score is in line with the industry averages, which is at -0.65.
Compared to an average industry Current Ratio of 6.11, SGMO is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.02, SGMO is worse placed to pay its short term obligations than its industry peers.
Based on the Altman-Z score of -1.74, we must say that SGMO is in the distress zone and has some risk of bankruptcy.
The Piotroski-F score of SGMO is 2.00. This is a very weak score and indicates problems in health and profitability for SGMO.
VS Industry
Debt/Equity (0) VS Industry: 41% outperformed.
15.37
0.00
Quick Ratio (2.75) VS Industry: 24% outperformed.
0.02
84.53
Current Ratio (2.75) VS Industry: 23% outperformed.
0.02
85.09
Altman-Z (-1.74) VS Industry: 45% outperformed.
-1,822.12
441.73
Dividend
Dividend Rating
SGMO does not give a dividend.
SANGAMO THERAPEUTICS INC3.65
NASDAQ:SGMO (12/2/2022, 7:01:55 PM)+0.09 (+2.53%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-03 2022-11-03/amc | Earnings (Next) | 02-22 2023-02-22 |
| Ins Owners | 0.99% | Inst Owners | 59.59% |
| Market Cap | 598.16M | Analysts | 80 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 5.34 | P/B | 1.93 |
| EV/EBITDA | -0.38 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | 6.3% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -3.03% |
| EPS Next Y | -8.58% | EPS Next 2Y | -4.63% |
| EPS Next 3Y | -1.58% | EPS Next 5Y | -1.23% |
| Revenue growth 1Y | 3.26% | Revenue growth 3Y | 9.42% |
| Revenue growth 5Y | 41.67% | Revenue growth Q2Q | -7.36% |
| Revenue Next Year | 1.08% | Revenue Next 2Y | 6.28% |
| Revenue Next 3Y | 9.18% | Revenue Next 5Y | 7.16% |
| Current Ratio | 2.75 | Quick Ratio | 2.75 |
| Altman-Z | -1.74 | F-Score | 2 |
| Debt/Equity | 0 | WACC | 8.94% |
| ROIC/WACC | N/A | ||
| ROA | -29.94% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | -158.67% | OM | -165.8% |
| Asset Turnover | 0.19 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA